Isfahan University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
The Role of Csf Biomarkers in Discriminating Between Cerebral Amyloid Angiopathy and Alzheimer’S Disease Patients: Systematic Review of Clinical Studies Publisher



Razmkhah Z1 ; Mosleh H2 ; Aghazadehhabashi K3 ; Pouraminaee F4 ; Samadian M5 ; Dadras H6 ; Ghayyem H7 ; Gorjizad M7 ; Dehghani M8 ; Eyvani K9 ; Alipour M10 ; Anar MA11
Authors
Show Affiliations
Authors Affiliations
  1. 1. Student Research Committee, School of Pharmacy, Shiraz University of Medical Sciences, Shiraz, Iran
  2. 2. Hearing Disorder Research Center, Loghman Hakim Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran
  3. 3. Student Research Committee, School of Medicine, Tabriz University of Medical Sciences, Tabriz, Iran
  4. 4. Department of Pathology, Schools of Medicine, Shiraz University of Medical Science, Shiraz, Iran
  5. 5. Skull Base Research Center, Loghman Hakim Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran
  6. 6. Student Research Committee, School of Medicine, Babol University of Medical Sciences, Babol, Iran
  7. 7. Student Research Committee, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran
  8. 8. Student Research Committee, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran
  9. 9. Department of Medicine, School of Medicine, Guilan University of Medical Sciences, Rasht, Iran
  10. 10. Department of Medicine, Faculty of Medicine, Tehran Medical Sciences Branch, Islamic Azad University, Tehran, Iran
  11. 11. Department of Medicine, College of Medicine, University of Arizona, Tucson, United States

Source: Caspian Journal of Neurological Sciences Published:2024


Abstract

Background: Alzheimer disease (AD), the most prevalent cause of dementia, is characterized by cognitive impairments and gradual memory loss. One of the most common neurological disorders affecting older people is cerebral amyloid angiopathy (CAA), which is defined by the buildup of amyloid β (Aβ) peptides in the walls of small and medium-sized cerebrocortical blood vessels as well as the leptomeninges. CAA and AD have several molecular, pathological, and clinical commonalities, like levels of Aβ peptides, total tau (t-tau), and phosphorylated tau (p-tau) in cerebrospinal fluid (CSF). Objectives: The main objective of this study is to compare Aβ and tau protein indicators in the CSF of individuals with CAA or AD versus a healthy control group. Materials & Methods: Medline, Web of Science, Google Scholar, and Embase databases were searched for relevant studies published from 2009 to 2022. Ten observational studies that reported the levels of t-tau, p-tau, Aβ40, Aβ42, or Aβ42/Aβ40 ratio in the CSF of AD and CCA patients were included. Results: The results showed that CAA and AD patient groups have higher p-tau and t-tau levels than the control group. Significantly lower concentrations of t-tau, p-tau, and Aβ40 are observed in the CSF of CAA compared to AD patients. Conclusion: We found that CSF p-tau, t-tau, and Aβ40 levels as reliable biomarkers can help diagnose and differentiate AD and CAA. Our study indicates that CSF biomarkers t-tau, p-tau, Aβ40, and Aβ42/Aβ40 ratio can be used in the clinical setting to distinguish between CAA and AD. © 2024 The Author(s); This is an open access article distributed under the terms of the Creative Commons Attribution License (CC-By-NC: https://creativecommons.org/licenses/by-nc/4.0/legalcode.en), which permits use, distribution, and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.